Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of
newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available …

Daratumumab is an anti-CD38 monoclonal antibody approved for use in multiple myeloma
in 2015 and under investigation for use in light-chain amyloidosis. We report a case of a …

Daratumumab (Darzalex) is a human CD38-directed monoclonal antibody that is approved
for the treatment of refractory multiple myeloma (MM). 1 In this article, we report a case of …

Daratumumab-containing regimens are an effective treatment for advanced cases of
multiple myeloma. Overall, daratumumab has a favourable safety profile, although rare side …

Introduction: Multiple myeloma has evolved markedly but the mortality remains high.
Daratumumab, a monoclonal antibody directly against CD38 antigen on the myeloma cells …

Background Daratumumab is a first-in-class anti-CD38 monoclonal antibody approved for
multiple myeloma. Because of the incidence and severity of infusion-related reactions with …

Daratumumab is very efficacious in multiple myeloma. Few reports are present about
efficacy in extramedullary myeloma. We report here daratumumab efficacy in extramedullary …

Background Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor
and immunomodulatory mechanisms of action, demonstrated clinical benefit as …

Multiple myeloma (MM) is a clonal proliferation of malignant bone marrow plasma cells with
high and uniform expression of CD38 [1]. Survival has improved with autologous stem cell …

Abstract Introduction: Daratumumab (DARA), a human anti-CD38 IgG1κ monoclonal
antibody, showed single agent activity in a phase 1/2 study of patients (pts) with relapsed or …